



OPEN ACCESS

APPROVED BY

Pathology and Oncology Research
Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Pathology and Oncology Research
Editorial Office,
✉ editorialoffice@por-journal.com

RECEIVED 22 November 2024

ACCEPTED 28 November 2024

PUBLISHED 12 December 2024

CITATION

Pathology and Oncology Research
Editorial Office (2024) Retraction:
Effects of gallotannin-enriched extract
of *Galla Rhois* on the activation of
apoptosis, cell cycle arrest, and
inhibition of migration ability in
LLC1 cells and LLC1 tumors.
Pathol. Oncol. Res. 30:1612042.
doi: 10.3389/pore.2024.1612042

COPYRIGHT

© 2024 Pathology and Oncology
Research Editorial Office. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License (CC BY). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which does
not comply with these terms.

Retraction: Effects of gallotannin-enriched extract of *Galla Rhois* on the activation of apoptosis, cell cycle arrest, and inhibition of migration ability in LLC1 cells and LLC1 tumors

Pathology and Oncology Research Editorial Office*

A Retraction of the Original Research Article

Effects of gallotannin-enriched extract of *Galla Rhois* on the activation
of apoptosis, cell cycle arrest, and inhibition of migration ability in
LLC1 cells and LLC1 tumors

by Kang MJ, Kim JE, Park JW, Choi HJ, Bae SJ, Choi SI, Hong JT and Hwang DY (2021). *Pathol. Oncol. Res.* 27:588084. doi: 10.3389/pore.2021.588084

Following publication, concerns were raised regarding the integrity of the images in the published figures. Two panels in Figure 5A appear to have been duplicated.

The authors were contacted by the POR Editorial Office and asked to provide the complete raw data for their study. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with POR policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Editor-in-Chief of Pathology & Oncology Research.

The authors agree to this retraction. The communication has been recorded by the publisher.




FIGURE 5
 Analysis for cell migration in GEGR treated LLC1 cells. **(A)** The migration ability of LLC1 cells was analyzed by the wound healing assay, following treatment with 25, 50, and 100 µg/mL of GEGR. Morphological images of cells were captured after 24 h and 48 h of incubation at 200 × magnification. Two to three wells per group were used for preparing the artificial injury, and the closure rates were calculated in duplicate for each sample. **(B, C)** After treatment with 25, 50, and 100 µg/mL of GEGR for 24 h, the expression levels of nine proteins were determined using an imaging densitometer. The level of each protein was presented relative to the intensity of actin. Two to three dishes per group were used in the preparation of the total cell homogenates, and Western blot analysis was assayed in duplicate for each sample. Data are reported as the means ± SD. *, p < 0.05 compared to the Vehicle treated group. †, p < 0.05 compared to the 25GEGR treated group. §, p < 0.05 compared to the 50GEGR treated group.